Recent clinical trials and research have demonstrated promising advancements in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). The FLAURA2 trial revealed improved overall survival when osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), was combined with chemotherapy as first-line therapy. Complementarily, Phase II studies show that combining the bispecific antibody-drug conjugate (ADC) iza-bren (BL-B01D1) with osimertinib achieved a 100% objective response rate in EGFR-mutated NSCLC patients, highlighting its potential as a powerful treatment option. Additional Phase III data indicate that adding chemotherapy to osimertinib after progression outside the central nervous system enhances progression-free survival, emphasizing the benefit of combination therapies. These developments, presented at prominent conferences such as the IASLC 2025 World Conference on Lung Cancer, mark critical progress in targeted oncology, offering new hope for patient management in advanced NSCLC.